VBI VACCINES INC (VBIV)
CA91822J2020 - Common Stock
VBIV gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. Both the profitability and financial health of VBIV have multiple concerns. VBIV is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
VBIV had negative earnings in the past year.
In the past year VBIV has reported a negative cash flow from operations.
VBIV had negative earnings in each of the past 5 years.
VBIV had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of VBIV (-111.34%) is worse than 80.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -111.34% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-71.38%
ROA(5y)-56.21%
ROE(3y)-490.56%
ROE(5y)-312.13%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VBIV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VBIV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VBIV has more shares outstanding
Compared to 5 years ago, VBIV has more shares outstanding
VBIV has a worse debt/assets ratio than last year.
2.2 Solvency
VBIV has an Altman-Z score of -13.90. This is a bad value and indicates that VBIV is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -13.90, VBIV is doing worse than 83.22% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -13.9 |
ROIC/WACCN/A
WACC9.93%
2.3 Liquidity
VBIV has a Current Ratio of 0.34. This is a bad value and indicates that VBIV is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of VBIV (0.34) is worse than 95.80% of its industry peers.
A Quick Ratio of 0.21 indicates that VBIV may have some problems paying its short term obligations.
VBIV has a worse Quick ratio (0.21) than 97.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.34 | ||
| Quick Ratio | 0.21 |
3. Growth
3.1 Past
The earnings per share for VBIV have decreased strongly by -90.48% in the last year.
VBIV shows a strong growth in Revenue. In the last year, the Revenue has grown by 548.76%.
Measured over the past years, VBIV shows a very strong growth in Revenue. The Revenue has been growing by 20.91% on average per year.
EPS 1Y (TTM)-90.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.33%
Revenue 1Y (TTM)548.76%
Revenue growth 3Y101.58%
Revenue growth 5Y20.91%
Sales Q2Q%150.31%
3.2 Future
VBIV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.46% yearly.
Based on estimates for the next years, VBIV will show a very strong growth in Revenue. The Revenue will grow by 64.62% on average per year.
EPS Next Y86.5%
EPS Next 2Y40.33%
EPS Next 3Y25.46%
EPS Next 5YN/A
Revenue Next Year-2.62%
Revenue Next 2Y60.85%
Revenue Next 3Y64.62%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VBIV. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VBIV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VBIV's earnings are expected to grow with 25.46% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.33%
EPS Next 3Y25.46%
5. Dividend
5.1 Amount
VBIV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VBI VACCINES INC
NASDAQ:VBIV (8/7/2024, 8:00:02 PM)
After market: 0.045 -0.02 (-31.09%)0.0653
-0.07 (-50.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.87M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -111.34% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.34 | ||
| Quick Ratio | 0.21 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-90.48%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y86.5%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)548.76%
Revenue growth 3Y101.58%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y